BioSpace News Archive

Policy

Emergex Signs an R&D Agreement with IMCB to Develop a Vaccine for the Emerging Threat of Hand, Foot & Mouth Disease

Emergex Vaccines Holding Limited announced that it has signed an R&D agreement with the Institute of Molecular and Cell Biology (IMCB) in Singapore to develop a fully synthetic vaccine against human viruses that cause Hand, Foot and Mouth Disease (HFMD).

June 27, 2019
·
4 min read
Deals

Delmar Pharmaceuticals Announces Termination Of Rights Offering

DelMar Pharmaceuticals, Inc., a biopharmaceutical company focused on the development and commercialization of new cancer therapies, announced it has terminated the rights offering of its securities previously announced on April 18, 2019.

June 27, 2019
·
3 min read
Deals

123Dentist’s ‘Dentist First’ Strategy Attracts Support from Equity Partner to Accelerate Growth Across Canada

Largest majority Canadian-owned network of dental practices continues to expand its platform across the country with strategic support and growth capital from Peloton Capital Management

June 27, 2019
·
4 min read
Policy

IncellDx Awarded Patent for Blood Collection Tube (BCT) That Activates HIV from Latent Cellular Reservoirs in the Tube

IncellDx, a leading single cell cancer diagnostics company, announced the issuing of a US patent for a blood collection tube that stimulates dormant HIV to produce virus in the infected cells while in the blood collection tube.

June 27, 2019
·
1 min read
Drug Development

Sierra Oncology Launches Campaign Exploring Non-Dilutive Strategic Options to Support Development of its DDR Assets

Sierra Oncology, Inc. announced plans to prioritize its existing resources on the development of momelotinib, its differentiated Phase 3 drug candidate for the treatment of patients with myelofibrosis.

June 27, 2019
·
7 min read
ProMIS Neurosciences’ PMN310 Shows Greater Therapeutic Potential vs. Other Amyloid-Beta-Directed Antibodies

Data presented at Keystone Symposium on Neurodegenerative Diseases

June 27, 2019
·
4 min read
Drug Development

Catabasis Pharmaceuticals Provides Update on Global Phase 3 PolarisDMD Trial for Edasalonexent at Parent Project Muscular Dystrophy 25th Annual Conference

Patient Identification Nearing Completion for Global Phase 3 PolarisDMD Trial for Edasalonexent in Duchenne Muscular Dystrophy

June 27, 2019
·
8 min read
Drug Development

Xeris Pharmaceuticals Doses First Patient in Phase 2 Trial Evaluating Its Developmental Ready-to-use Glucagon in Patients at Risk From Hypoglycemia Following Bariatric Surgery

Xeris Pharmaceuticals, Inc. announced that is has dosed the first subject in a Phase 2 trial with its developmental ready-to-use glucagon in patients who experience hypoglycemic episodes following bariatric surgery.

June 27, 2019
·
6 min read
Deals

Vaxess Technologies Closes Final Tranche of $8.2 Million Series A and Appoints Dr. Purnanand Sarma to the Board

Vaxess Technologies, a biotechnology company redefining drug delivery with the silk-powered MIMIX smart release patch, announced it has closed the final tranche of an $8.2 million Series A round.

June 27, 2019
·
3 min read
BioMidwest

Vireo Health Announces Inclusion in Horizons Marijuana Index ETFs

Vireo Health International, Inc. (“Vireo” or the “Company”) (CSE: VREO; OTCQX: VREOF), a leading science-focused, multi-state cannabis company, today announced that its shares have been included in the Horizons US Marijuana Index ETF (HMUS) and the Horizons Emerging Marijuana Growers Index ETF (HMJR).

June 27, 2019
·
2 min read